Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panitumumab - Amgen

Next Previous
Drug Profile

Panitumumab - Amgen

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Grupo Espanol Multidisciplinario del Cancer Digestivo; Hellenic Cooperative Oncology Group; Netherlands Cancer Institute; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center; Wissenschaftlicher Service Pharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Anal cancer; Bladder cancer; Breast cancer; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Triple negative breast cancer
  • Phase I/II Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 30 May 2025 Pharmacodynamics data from a phase III trial in Colorectal cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 30 May 2025 Updated efficacy and adverse events data from a phase Ib CodeBreake 101 trial in Colorectal cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 31 May 2024 Updated efficacy and adverse events data from a phase III trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top